宫颈癌PET阳性淋巴结SBRT推量是否可行?基于肿瘤控制概率与QUANTEC标准的评估
本研究回顾性纳入10例宫颈癌伴PET阳性淋巴结转移患者,在体外放疗45 Gy、三维适形推量5.4-9 Gy及高剂量率腔内放疗16-30 Gy基础上,用21 Gy、24 Gy或30 Gy的SBRT方案替代三维适形推量并计算肿瘤控制概率。结果显示SBRT推量提高TCP值,30 Gy组全部满足QUANTEC危及器官剂量限值。
要点
- 10例中30%接受常规推量的患者出现复发。
- SBRT方案TCP为88%±7%(21 Gy)、96%±1%(24 Gy)、99%±1%(30 Gy),常规推量TCP为25%±11%。
- SBRT 21 Gy组全部、24 Gy组90%、30 Gy组70%的病例满足QUANTEC膀胱、直肠和肠道剂量限值。
核心结论
- SBRT推量30 Gy可在不违反QUANTEC危及器官限值的情况下实施,且无论输入参数如何,SBRT均提高TCP值。
研究设计与样本
- 回顾性纳入10例接受体外放疗45 Gy、三维适形推量5.4-9 Gy及 tandem-and-ovoid 高剂量率腔内放疗16-30 Gy的宫颈癌伴PET阳性淋巴结转移患者。
- 生成SBRT计划,分别以21 Gy、24 Gy或30 Gy替代三维适形推量,采用α/β=10(PET阳性淋巴结)和α/β=3(危及器官)计算2 Gy分次等效剂量图。
- TCP值采用逻辑TCP模型计算,模型输入参数D50和Gamma50=2分别基于本机构和文献的临床结局数据建模。
- 危及器官保护采用QUANTEC剂量限值评估。
主要发现
- 10例接受常规推量的患者中30%出现复发。
- 基于文献淋巴结SBRT临床结局数据时,SBRT方案TCP为88%±7%(21 Gy)、96%±1%(24 Gy)、99%±1%(30 Gy),常规淋巴结推量TCP为25%±11%。
- 基于本机构结局数据时,SBRT方案TCP为97%±2%(21 Gy)、99%±0%(24 Gy)、100%±0%(30 Gy),常规淋巴结推量TCP为58%±15%。
- SBRT推量计划的肿瘤覆盖剂量(D90)平均分别比常规淋巴结推量计划高32.34 Gyαβ=10(21 Gy)、37.78 Gyαβ=10(24 Gy)和55.54 Gyαβ=10(30 Gy)。
- QUANTEC危及器官剂量限值在SBRT淋巴结21 Gy组全部病例、24 Gy组90%病例和30 Gy组70%病例中满足膀胱、直肠和肠道限值。
关键数值与推荐
- SBRT推量剂量为21 Gy、24 Gy或30 Gy,替代三维适形推量5.4-9 Gy。
- TCP模型输入参数D50和Gamma50=2,分别基于本机构和文献临床结局数据建模。
- 危及器官评估采用QUANTEC剂量限值。
临床怎么用
- 原文结论指出SBRT推量30 Gy可在不违反QUANTEC危及器官限值的情况下实施,且SBRT提高TCP值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to examine the feasibility of stereotactic body radiation therapy (SBRT) as an external beam radiation therapy boost to positron emission tomography (PET) positive lymph nodes (LN) in patients with cervical cancer and to evaluate overall tumor control probability (TCP) increase. METHODS AND MATERIALS: Ten patients with cervical cancer and PET positive LN metastasis who received external beam radiation therapy (45 Gy), followed by a 3-dimensional conformal radiation therapy boost (5.4-9 Gy) and tandem-and-ovoid high-dose-rate brachytherapy (16-30 Gy) were retrospectively enrolled in this study. SBRT plans were generated using 21 Gy, 24 Gy, or 30 Gy as a replacement for 3-dimensional conformal radiation therapy boost. The 2 Gy-per-fraction equivalent dose maps were made using an α/β value of 10 for PET positive LNs and 3 for organs at risk (OARs). TCP values were calculated using a logistic TCP model, where 2 input parameters (D50 and Gamma50 = 2) were modeled by 2 clinical outcomes: our institution and the literature. OAR sparing was evaluated using Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) dose limits. RESULTS: Thirty percent of 10 patients receiving conventional boost experienced recurrence. The TCP of the SBRT schemes was 88% ± 7% (97% ± 2%; 21 Gy), 96% ± 1% (99% ± 0%; 24 Gy), and 99% ± 1% (100% ± 0%; 30 Gy), and the conventional LN-boost TCP value was 25% ± 11% (58% ± 15%) when TCP input parameters were based on published clinical outcome data for LN SBRT treatments (institutional outcome data). The tumor coverage doses (D90) of the SBRT boost plans were on average 32.34 Gyαβ=10 (21 Gy), 37.78 Gyαβ=10 (24 Gy), and 55.54Gyαβ=10 (30 Gy) higher than the conventional LN boost plan. The QUANTEC OAR dose constraints were met for the bladder, rectum, and bowel in all cases for the SBRT LN 21 Gy group, and in 90% and 70% of cases in the SBRT LN 24 Gy and SBRT LN 30 Gy groups, respectively. CONCLUSIONS: An SBRT boost dose of 30 Gy can be delivered without compromising QUANTEC OAR limits. The use of SBRT increases TCP values, regardless of the input parameters.
引用
- Snyder JE, Willett AB, Sun W, et al. Is SBRT Boost Feasible for PET Positive Lymph Nodes for Cervical Cancer? Evaluation using Tumor Control Probability and QUANTEC Criteria. Pract Radiat Oncol. 2018. PMID: 30415074. doi:10.1016/j.prro.2018.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。